➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: July 27, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Resiquimod

Email this page to a colleague

« Back to Dashboard

What is the drug development status for Resiquimod?

Resiquimod is an investigational drug.

There have been 17 clinical trials for Resiquimod. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2005.

The most common disease conditions in clinical trials are Warts, Melanoma, and Influenza, Human. The leading clinical trial sponsors are Graceway Pharmaceuticals, LLC, Mayo Clinic, and National Cancer Institute (NCI).

Recent Clinical Trials for Resiquimod
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid TumorsAscendis Pharma Oncology Division A/SPhase 1/Phase 2
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor PatientsCase Comprehensive Cancer CenterPhase 1/Phase 2
Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) AgonistsUniversity of British ColumbiaPhase 1

See all Resiquimod clinical trials

Clinical Trial Summary for Resiquimod

Top disease conditions for Resiquimod
Top clinical trial sponsors for Resiquimod

See all Resiquimod clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.